文献速递白血病造血干细胞移植与细胞治疗

挽救性化疗后脐带血过继免疫治疗难治性髓系恶性肿瘤:嵌合与疗效

Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.
PubMed 文献 · Blood Adv · 2020-01-01

We conducted a prospective evaluation of cord blood (CB)-derived adoptive cell therapy, after salvage chemotherapy, for patients with advanced myeloid malignancies and poor prognosis. Previously, we reported safety, feasibility, and preliminary efficacy of this approach.…

要点

  • 强化化疗后脐带血过继细胞治疗在难治性AML中可行,42%患者获得缓解。
  • 脐带血单位来源嵌合是缓解的强预测因素(P < .001)。
  • 脐带血单位淋巴细胞含量和既往移植与嵌合相关(P < .01)。

核心结论

  • 脐带血来源过继细胞疗法对难治性急性髓系白血病可行且有效。
  • 缓解依赖于嵌合,提示脐带血细胞疗法存在移植物抗白血病效应。

研究设计与样本

  • 前瞻性评估,31例晚期髓系恶性肿瘤患者接受强化化疗后脐带血输注。
  • 选择与受者共享遗传性父源抗原和/或非遗传性母源抗原的脐带血单位。
  • 缓解定义为治疗后2周低增生骨髓中原始细胞<5%。

主要发现

  • 脐带血单位淋巴细胞含量和既往移植与嵌合相关(P < .01)。
  • 3例发生轻度细胞因子释放综合征,2例1级和2例4级移植物抗宿主病。
  • 7例缓解者和6例无缓解者(额外治疗后)后续接受移植;5例存活(随访5-47个月)。

关键数值与推荐

  • 缓解标准:治疗后2周低增生骨髓原始细胞<5%。
  • 嵌合预测缓解的P值:P < .001。
  • 淋巴细胞含量和既往移植与嵌合相关的P值:P < .01。

临床怎么用

  • 对于难治性AML患者,可考虑强化化疗后脐带血过继细胞治疗。
  • 库存脐带血单位易于获取用于治疗。
  • 监测脐带血单位来源嵌合有助于预测治疗反应。

局限性

  • 样本量较小(31例)。
  • 非随机对照,历史数据比较。
  • 随访时间范围5-47个月,部分患者后续接受移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a prospective evaluation of cord blood (CB)-derived adoptive cell therapy, after salvage chemotherapy, for patients with advanced myeloid malignancies and poor prognosis. Previously, we reported safety, feasibility, and preliminary efficacy of this approach. We present updated results in 31 patients who received intensive chemotherapy followed by CB infusion and identify predictors of response. To enhance the antileukemic effect, we selected CB units (CBU) with shared inherited paternal antigens and/or noninherited maternal antigens with the recipients. Twenty-eight patients with acute myeloid leukemia (AML), 2 with myelodysplastic syndrome, and 1 in chronic myeloid leukemia myeloid blast crisis were enrolled; 9 had relapsed after allogeneic transplant. Response was defined as <5% blasts in hypocellular bone marrow at 2 weeks after treatment. Thirteen patients (42%) responded; a rate higher than historical data with chemotherapy only. Twelve had CBU-derived chimerism detected; chimerism was a powerful predictor of response (P < .001). CBU lymphocyte content and a prior transplant were associated with chimerism (P < .01). Safety was acceptable: 3 patients developed mild cytokine release syndrome, 2 had grade 1 and 2 had grade 4 graft-versus-host disease. Seven responders and 6 nonresponders (after additional therapy) received subsequent transplant; 5 are alive (follow-up, 5-47 months). The most common cause of death for nonresponders was disease progression, whereas for responders it was infection. CB-derived adoptive cell therapy is feasible and efficacious for refractory AML. Banked CBU are readily available for treatment. Response depends on chimerism, highlighting the graft-versus-leukemia effect of CB cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT02508324.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chaekal OK, Scaradavou A, Masson Frenet E, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020. PMID: 33091124. doi:10.1182/bloodadvances.2020002805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。